Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00547508 · ClinicalTrials.gov registry record · Phase 3
To Determine How Different Doses of Tadalafil Work on Getting and Keeping an Erection 26 or 36 Hours After Taking
A Phase 3 study of Impotence, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 485
- Enrollment target
- 1
- Study location
NCT00547508: Completed Phase 3 study of Impotence, sponsored by Eli Lilly and Company.
NCT00547508 is a Phase 3 study of Impotence that has completed, run by Eli Lilly and Company. The registered enrollment target is 485 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00547508, a Phase 3 study of Impotence, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 485 participants
- Enrollment target
- 1
- Study location
Study Summary
Study to see how effective different doses of tadalafil are for getting and keeping an erection when sex is attempted after a certain number of hours.
Conditions Studied
Interventions
- DRUG placebo
- DRUG tadalafil
Study Locations (1)
Tennessee
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 485 participants |
| Start Date | 2002-10 |
| Est. Completion | 2003-09 |
| Phase | Phase 3 |
What the finished NCT00547508 record still lists
NCT00547508 is an interventional study that assigns participants to a tested intervention. The registered 485 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (37% lower).
The record links to 1 condition, with Impotence appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00547508 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT00547508 about?
NCT00547508 is a clinical study titled "To Determine How Different Doses of Tadalafil Work on Getting and Keeping an Erection 26 or 36 Hours After Taking". Study to see how effective different doses of tadalafil are for getting and keeping an erection when sex is attempted after a certain number of hours.
What is the current status of trial NCT00547508?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 485 participants. The study started on 2002-10. Estimated completion is 2003-09.
What conditions does trial NCT00547508 study?
This clinical trial studies the following conditions: Impotence.
What interventions are being tested in trial NCT00547508?
The interventions under investigation include: placebo (DRUG), tadalafil (DRUG).
Who is sponsoring clinical trial NCT00547508?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00547508 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00547508's enrollment target sits among peer trials
485 790th of 2000 higher than 1,210 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07124910 · 485 participants · Phase 3
Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
- NCT06420531 · 486 participants · NA
Milk And Growth In Children (MAGIC) Born Very Preterm: A Randomized Trial
- NCT07097142 · 486 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
- NCT05421741 · 484 participants · Phase 4
Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia